Fact-checked by Grok 2 weeks ago

Scott Gottlieb

Scott Gottlieb is an physician, healthcare expert, and who served as the 23rd Commissioner of the U.S. (FDA) from May 11, 2017, to April 5, 2019. Prior to his commissioner role, Gottlieb held senior positions at the FDA, including for Medical and Scientific Affairs, and worked as a resident fellow at the (AEI), focusing on regulatory and healthcare issues. As FDA head under President Trump, he advanced policies to expedite approvals—achieving a record number to foster competition and reduce costs—and created novel pathways for approving complex generics, while aggressively targeting youth vaping through enforcement against flavored e-cigarettes and proposing flavor bans. His tenure also emphasized modernizing FDA processes for innovative therapies, though it faced criticism for his pre-appointment ties and later "revolving door" moves to private sector roles. After resigning to spend more time with family, Gottlieb rejoined (NEA) as a partner in healthcare investing, became a board member, was elected non-executive chair of Illumina's board in 2025, and resumed his AEI senior fellowship, continuing commentary on and regulation.

Early life and education

Upbringing and family influences

Scott Gottlieb was born on June 11, 1972, and raised in . He is the son of Dr. Stanley Gottlieb, a , and Marsha Gottlieb, a schoolteacher. His family maintained a close-knit dynamic, with both parents residing in East Brunswick during his upbringing. The Gottlieb family is Jewish, reflecting a cultural and religious heritage common in suburban communities of the era. Limited public details exist on specific childhood experiences or direct familial influences on his later career in and , though his father's profession in —a medical specialty—aligned with Gottlieb's eventual pursuit of an MD degree. No verified accounts indicate unusual or pivotal events in his early years beyond this standard professional-family background.

Academic and medical training

Gottlieb earned a degree in from in 1994. He then attended the Icahn School of Medicine at , receiving his degree in 1999. Following medical school, Gottlieb completed a residency in internal medicine at from 1999 to 2002.

Professional career

Initial roles in medicine and policy

Following completion of his residency in internal medicine at in in 2002, Gottlieb practiced as a hospitalist while also serving as a clinical at School of Medicine in . In this capacity, he focused on , reflecting his training as an internist. Concurrently, Gottlieb engaged in medical writing and editing, serving as senior editor for , a publication of the , from 1996 to 2001, and as a for the British Medical Journal from 1997 to 2005, where he contributed to discussions on and clinical issues. Gottlieb's entry into formal policy roles began in 2002 when he joined the as a resident fellow, focusing on studies. This position overlapped with his first role in 2003, when he joined the (FDA) as a senior advisor to Commissioner and as director of medical policy development, assisting in shaping regulatory approaches to medical products. In 2004, he transitioned to a senior policy advisor position at the (CMS), where he contributed to the implementation of the drug benefit program under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. These early policy engagements emphasized accelerating drug approvals and integrating market mechanisms into public health programs.

FDA and CMS positions (2003–2007)

Gottlieb began his tenure in federal health agencies in early 2003 as a senior advisor to FDA Commissioner , assisting with policy development, speechwriting, and strategic communications on medical innovation and regulatory matters. He also held the position of Director of Medical Policy Development at the FDA during this period, focusing on advancing policies for drug and medical technology approvals amid efforts to streamline regulatory processes under the Bush administration. In spring 2003, Gottlieb transitioned to the (CMS) as a senior policy advisor to Administrator , following his former FDA superior who had moved to lead CMS. In this role, extending through 2004, he advised on Medicare program policies, including coverage determinations for medical technologies and pharmaceuticals during the implementation phase of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, which introduced the Part D outpatient prescription drug benefit effective in 2006. Gottlieb returned to the FDA in 2005 as for Medical and Scientific Affairs, serving until 2007 in what was effectively the agency's second-ranking scientific leadership position. This role involved overseeing medical product policy, scientific review processes for drugs, biologics, and devices, and coordinating with external stakeholders on evidence-based regulatory decisions under Commissioner Lester Crawford and later Andrew von Eschenbach. His work supported broader agency initiatives, such as enhancing post-market surveillance and fostering public-private collaborations to address bottlenecks in innovative therapies, though specific outcomes tied directly to his tenure remain documented primarily through agency-wide reports rather than individualized attributions.

Private sector engagements (2007–2017)

Following his departure from federal service at the (FDA) and (CMS) in 2007, Gottlieb joined (NEA), a global firm, as a Venture Partner on its healthcare investment team, a role he held until 2017. In this capacity, he advised on investments in and healthcare startups, leveraging his regulatory expertise to evaluate opportunities in and medical innovation. NEA's portfolio during this period included numerous life sciences companies, though specific deals tied directly to Gottlieb's involvement were not publicly detailed beyond his general advisory function. From 2013 to , Gottlieb served as Managing Director at T.R. Winston & Company, a Los Angeles-based merchant bank specializing in healthcare and life sciences transactions, where he focused on mergers, acquisitions, and strategic advisory for pharmaceutical and biotech firms. In 2016 alone, he earned approximately $1.85 million from this firm, contributing to his overall compensation exceeding $3 million that year from private sector activities. He also held board positions at companies such as Tolero Pharmaceuticals, a Utah-based firm developing cancer therapies, which was acquired by Sumitomo Dainippon Pharma in late 2017 for $560 million. Throughout 2007–2017, Gottlieb engaged in consulting and advisory work for more than 20 healthcare companies, generating millions in fees from services including regulatory strategy and policy guidance. These roles encompassed financial interests in 19 entities disclosed during his 2017 process, spanning pharmaceuticals, biotech, and devices, though he maintained no equity stakes in T.R. Winston itself. Concurrently, he practiced as an at Tisch Hospital, balancing clinical work with his investment and advisory pursuits.

FDA Commissioner tenure (2017–2019)

Scott Gottlieb was nominated by President Donald Trump to serve as the 23rd Commissioner of Food and Drugs and confirmed by the U.S. Senate on May 9, 2017, in a 57-42 vote. He was sworn in on May 11, 2017. During his tenure, Gottlieb prioritized accelerating the approval of innovative therapies, enhancing generic drug competition, and addressing public health threats including the opioid crisis and youth tobacco use. Under Gottlieb's leadership, the FDA approved a record 59 novel drugs in 2018, an increase from 46 in 2017, focusing on therapies for serious conditions through expedited pathways. The agency also set records for approvals, with 763 in 2017 and 781 in 2018, aimed at lowering costs and increasing access by facilitating competition against branded drugs. Gottlieb initiated reforms to streamline generic reviews, including better resolution of patent disputes and incentives for complex generics. On opioids, the FDA under Gottlieb requested the withdrawal of reformulated Opana ER ( extended-release) in June 2017, citing risks from abuse via injection; manufacturer Pharmaceuticals agreed to remove it from the market in July 2017, marking the first such FDA action based on abuse liability. The agency advanced non- options and aimed to reduce overall opioid prescribing exposure, though it also approved Dsuvia, a sublingual formulation for acute pain, in November 2018. Gottlieb addressed rising youth e-cigarette use by declaring a youth vaping epidemic in 2018 and advancing regulatory timelines, requiring premarket tobacco product applications (PMTAs) for e-cigarettes by May 2020 instead of 2022 to assess safety and marketing restrictions. The FDA proposed limits on flavored e-liquids in non-tobacco retail settings to curb appeal to minors while preserving access for adult smokers seeking cessation aids. Gottlieb announced his resignation on March 5, 2019, effective April 5, 2019, stating he wished to spend more time with his family after fulfilling his commitment to place the FDA on a strong trajectory against challenges.

Ventures and advisory roles (2019–present)

Following his resignation as FDA Commissioner on April 5, 2019, Gottlieb rejoined the as a resident fellow, where he focuses on , regulatory issues, and innovation. In May 2019, he returned to (NEA) as a partner on the firm's healthcare investment team, advising on investments in biopharmaceuticals, diagnostics, and companies; prior to his FDA tenure, he had served as a venture partner at NEA from 2007 to 2017. Gottlieb joined the board of directors of Pfizer Inc. in June 2019, serving as chair of the Regulatory and Compliance Committee and as a member of the Science and Technology Committee. In September 2019, he became a board director at Aetion, a healthcare technology firm specializing in real-world evidence analytics for regulatory and clinical decision-making. He joined the board of Illumina Inc., a genomics sequencing company, in February 2020. Gottlieb also serves on the boards of Tempus AI, a precision medicine company leveraging for and other therapeutic areas, as well as other ventures including Resilience Biotechnologies and Comanche Biopharma, through his NEA affiliations. In these roles, he provides strategic guidance on regulatory navigation, product development, and market entry for biotech and health tech firms.

Policy views and contributions

Drug approval processes and regulatory reform

During his tenure as FDA Commissioner from May 2017 to April 2019, Scott Gottlieb pursued reforms aimed at accelerating drug approvals while maintaining safety standards, including implementation of the provisions to expedite development and review of innovative therapies. His administration approved a record number of generic drugs in 2017 and 2018, yielding an estimated $26 billion in savings for U.S. consumers through increased competition. The FDA under Gottlieb also approved more novel drugs in 2017 than in any year since 1996, emphasizing transparency and predictability in the review process to foster investment. Gottlieb advocated for adaptive designs to shorten approval timelines by years and reduce development costs, alongside broader drug labeling to expand to larger populations without requiring additional trials for minor variations. In June 2017, he launched the Drug Competition Action Plan to dismantle barriers to entry, such as complex manufacturing requirements and settlements, followed by a January 2018 strategic roadmap to streamline approvals and finalize interchangeability guidance. He defended the accelerated approval pathway, noting improvements in validation since the prior decade that enhanced its reliability for serious conditions, and criticized payer restrictions on such s as detrimental to . In a 2018 congressional , Gottlieb addressed antitrust issues in the approval process, arguing that FDA policies should promote without stifling , including scrutiny of practices delaying launches. Post-tenure, Gottlieb has called for additional regulatory reforms to bolster U.S. biopharma competitiveness, particularly against , by streamlining early-stage development, modernizing evidence generation for rare diseases, and reducing approval bottlenecks to match faster foreign timelines. He contends that operational delays, rather than scientific deficits, hinder U.S. progress, urging lowered costs and clearer pathways for domestic .

Public health initiatives (opioids, vaping, and beyond)

Gottlieb prioritized combating the through regulatory measures aimed at curbing overprescribing while expanding access to treatment. In 2017, the FDA under his expanded the Risk Evaluation and Mitigation Strategy (REMS) program for , mandating prescriber education on , safe use, and alternatives to mitigate risks of abuse and overdose. He advocated for increased use of medication-assisted treatment (MAT), which integrates FDA-approved medications like and with counseling, estimating it could reduce illegal use and improve recovery outcomes for those with . Gottlieb testified before on October 4, 2017, outlining a multifaceted federal response that included enhancing prevention services, supporting recovery infrastructure, and fostering novel non-addictive pain therapies to address the crisis's health and economic toll, which by then involved over 42,000 overdose deaths annually. To promote alternatives to opioids, Gottlieb issued guidance in 2017 encouraging pharmaceutical development of non-opioid analgesics, emphasizing FDA's benefit-risk framework to expedite approvals for therapies targeting pain pathways without addiction potential. In a 2017 JAMA commentary co-authored with FDA's Janet Woodcock, he detailed leveraging agency expertise to reassess opioid approvals, reduce misuse through labeling reforms, and balance access for legitimate medical needs against epidemic drivers like high-dose formulations. These efforts contributed to a reported decline in opioid prescribing rates during his tenure, though critics argued earlier FDA approvals had fueled the crisis by underemphasizing abuse risks in labeling. On vaping and e-cigarettes, Gottlieb declared a usage "" in November 2018, citing data showing over 3.6 million U.S. middle and high students using e-cigarettes, with pod-based devices like driving a 78% increase in high school use that year. He advanced restrictions on flavored products, proposing in March 2019 to limit sales of non- flavors in closed-pod systems and disposable e-cigarettes to combat adolescent initiation while preserving harm-reduction potential for adult smokers transitioning from combustible . The FDA finalized a compliance policy in March 2019 permitting limited activities like device demonstrations but enforcing premarket review deadlines, with Gottlieb warning of market removal for non-compliant products if trends persisted. Beyond opioids and vaping, Gottlieb's initiatives targeted broader nicotine addiction and tobacco control. In 2017, he outlined steps to render combustible cigarettes "minimally or non-addictive" via reduction targets, aiming to prevent intergenerational by undermining cigarettes' appeal to without banning them outright. This aligned with the FDA's 2017 Comprehensive Plan for and Regulation, which sought to phase down levels in cigarettes and evaluate e-cigarettes' role in cessation versus uptake. He also pushed for expanded oversight of novel tobacco products, including warnings against unauthorized cessation therapies and enforcement against illicit e-cigarette sales contributing to access. These measures reflected a regulatory philosophy prioritizing empirical protection data over industry partnerships, though post-tenure reflections acknowledged challenges in balancing harm reduction with preventing new dependencies.

Perspectives on pandemics and vaccine policy

In his 2021 book Uncontrolled Spread: Why Crushed Us and How We Can Defeat the Next Pandemic, Scott Gottlieb critiqued the ' handling of the outbreak as a failure of preparedness, attributing it to inadequate surveillance systems, delayed testing capacity, and underinvestment in infrastructure despite prior warnings from outbreaks like in 2003 and in 2012. He argued that the virus exploited gaps in domestic manufacturing for diagnostics and therapeutics, as well as overreliance on global supply chains vulnerable to disruption, leading to over 1 million U.S. deaths by mid-2022. Gottlieb emphasized causal factors such as the Centers for Disease Control and Prevention's (CDC) centralized structure, which slowed response times compared to decentralized models in countries like . To enhance future preparedness, Gottlieb recommended restructuring the CDC to prioritize rapid mitigation of known pathogens over broad epidemiological , expanding U.S.-based of and antivirals, and establishing a dedicated national stockpile with annual refreshment drills. He advocated for preemptive investments in platform technologies like mRNA for faster vaccine adaptation and international partnerships for early warning systems, estimating that such measures could reduce response times from months to weeks in subsequent outbreaks. These proposals drew from empirical reviews of the U.S. playbook's shortcomings, including its focus on scenarios rather than novel coronaviruses. On vaccine policy, Gottlieb supported accelerated development during the , urging the FDA in April 2020 to collaborate with industry on prioritizing 1-2 leading candidates for clinical trials to expedite emergency use authorizations, a strategy that contributed to initial approvals by December 2020. He viewed as effective in leveraging public-private partnerships to deliver vaccines at scale, crediting it with enabling thresholds by late 2021, though he cautioned that alone would not immediately end restrictions due to infections and variant emergence. However, he opposed broad federal mandates, arguing in September 2021 that Biden's requirements for large employers could erode and backfire by fueling resistance, and instead favored targeted, localized incentives or employer-led policies. More recently, Gottlieb has warned against declining rates, predicting in November 2024 that influences undermining routine immunizations could lead to resurgences of preventable diseases like , with U.S. rates potentially dropping below the 95% threshold needed for . In June 2025, he criticized changes to the CDC's Advisory Committee on Immunization Practices, asserting that prioritizing over would have long-term consequences for outcomes. These positions reflect his broader emphasis on empirical data from clinical trials and outbreak over politicized debates.

Controversies and criticisms

Pharmaceutical industry connections

Prior to his appointments at the (FDA), Scott Gottlieb maintained extensive connections to the and sectors. From 2007 to 2017, he served as a venture partner at (NEA), a firm that invests heavily in healthcare and life sciences companies, including startups focused on . During this period and earlier, Gottlieb held or had held seats on the boards of directors for at least eight companies, several of which were involved in pharmaceutical innovation, such as Tolero Pharmaceuticals (oncology drug development) and Gradalis (biotech therapies for cancer). Following his tenure as FDA commissioner from May 2017 to April 2019, Gottlieb deepened these ties through high-profile board roles at major industry players. In June 2019, he was elected to the board of directors of Pfizer Inc., the world's largest pharmaceutical company by revenue at the time, where he serves on the Regulatory and Compliance Committee and the Science and Technology Committee; his compensation for the role included at least $335,000 in stock and cash for 2018 equivalents, though exact figures post-appointment vary. He also joined boards of Illumina Inc. (genomic sequencing technologies used in drug discovery), Tempus AI (AI-driven precision medicine for oncology and other areas), and Aetion (real-world evidence platforms supporting pharmaceutical regulatory approvals). Additionally, upon returning to NEA as a special partner in 2019, Gottlieb continued advising on healthcare investments, including in biopharma ventures. These affiliations have fueled debates over potential conflicts of interest, often framed as examples of the "revolving door" between government regulation and industry. Critics, including advocacy groups like Public Citizen, argued that Gottlieb's pre-FDA pharma board seats and rapid post-FDA move to Pfizer—mere months after leaving the agency—could undermine public trust in FDA impartiality and influence regulatory leniency toward drug pricing and approvals. U.S. Senator Elizabeth Warren urged his resignation from Pfizer's board in July 2019, citing risks of insider knowledge benefiting industry over public health. Gottlieb defended the appointments, asserting no legal conflicts under federal ethics rules (which impose a one-year cooling-off period for certain contacts) and emphasizing his policy expertise as an asset to boards without compromising prior regulatory decisions. Supporters, including industry analysts, noted such transitions are common among FDA alumni, providing valuable regulatory insights to companies navigating complex approvals.

Revolving door allegations

Prior to his 2017 nomination as FDA Commissioner, Scott Gottlieb held positions with multiple pharmaceutical and firms, including serving as a venture partner at from 2007 to 2017, where he invested in and companies, and as a board member or advisor to entities such as GlaxoSmithKline, Tolero Pharmaceuticals, Gradalis, and Glytec. He also received over $559,000 in consulting and speaking fees from drug and companies, including , , and Bristol-Myers Squibb, between August 2013 and December 2016. Advocacy groups such as opposed his nomination, arguing that these extensive industry ties spanning over a decade created inherent conflicts of interest and risked prioritizing corporate interests over regulation. To address potential conflicts, Gottlieb committed during his confirmation process to recuse himself for one year from FDA decisions involving approximately 20 healthcare companies with which he had worked, and to divest from certain financial holdings tied to the industry. Critics, including outlets like STAT News and the , contended that such measures were insufficient to halt the broader "" dynamic at the FDA, where regulators' industry experience could foster leniency in approvals or enforcement. Following his resignation from the FDA on April 5, 2019, Gottlieb joined the board of directors of Pfizer on June 27, 2019, less than three months later, a position that included service on the company's regulatory and compliance committee and compensation exceeding $330,000 in cash and stock based on prior board pay structures. This move drew sharp rebukes, with Senator Elizabeth Warren describing it as "influence peddling that smacks of corruption" and calling for his resignation, citing the risk that Pfizer—facing billions in potential FDA-related decisions—could leverage Gottlieb's expertise and connections to sway future regulatory outcomes. Gottlieb defended the appointment, stating it complied with federal ethics rules including a one-year cooling-off period barring involvement in matters he personally handled at the FDA, and emphasized his intent to provide independent oversight rather than industry favoritism. highlighted the episode as emblematic of systemic issues eroding agency trust, though such transitions by former FDA leaders to pharmaceutical boards have been recurrent across administrations.

Debates over regulatory decisions

Gottlieb's efforts to expedite drug approval processes, including reforms to accelerate reviews and the use of , drew criticism for potentially prioritizing industry innovation over . Advocates argued that such changes addressed longstanding bottlenecks, with the FDA approving a record 59 novel drugs in 2018, many for rare diseases and . However, consumer and patient advocacy groups, including Action, contended that loosening standards risked inadequate post-market surveillance and echoed concerns from a 2017 STAT analysis highlighting how prior deregulatory postures had enabled unsafe products to reach markets. Gottlieb maintained that empirical data from accelerated pathways, such as designations, demonstrated improved access without compromising efficacy, as evidenced by subsequent low recall rates for approved therapies. In addressing the opioid crisis, Gottlieb introduced a policy in November 2018 requiring new opioid analgesics to demonstrate clinical advantages over existing treatments, such as reduced abuse potential or superior efficacy, before approval—a shift from prior standards focused solely on individual drug safety. This measure, applied narrowly to opioids amid debates over FDA's historical contributions to over-approval, blocked several candidates but faced pushback from pharmaceutical stakeholders who viewed it as overly restrictive, potentially stifling beneficial innovations like abuse-deterrent formulations. Critics, including Senator Edward Markey during confirmation hearings, highlighted Gottlieb's pre-tenure opposition to certain opioid risk mitigation strategies, questioning his commitment despite the policy's implementation, which aligned with CDC guidelines on labeling and approvals. Regulatory actions on electronic cigarettes and vaping products ignited significant contention, particularly after Gottlieb declared a youth vaping "epidemic" in November 2018 and proposed removing flavored pod cartridges to curb adolescent use, which had risen to 20.8% among high schoolers per FDA-monitored surveys. The agency threatened market removal for non-compliant products and pursued enforcement against unauthorized sales, yet delayed full premarket review deadlines to May 2020, prompting lawsuits from organizations alleging undue leniency toward industry. Post-resignation, reflected that the FDA had "struck the wrong balance" by not enforcing timelines more aggressively earlier, allowing black-market growth, though data showed his tenure reduced youth initiation rates via targeted warnings and restrictions on marketing. These decisions underscored tensions between immediate and long-term regulatory feasibility, with vaping proponents arguing flavors aided adult , per studies cited in FDA dockets.

Writing and public commentary

Books and major publications

Gottlieb authored Uncontrolled Spread: Why COVID-19 Crushed Us and How We Can Defeat the Next Pandemic, published by Harper in September 2021, which became a New York Times bestseller. The book examines the U.S. government's response to the COVID-19 pandemic, attributing early failures to inadequate biosurveillance systems, delayed travel restrictions from China in January 2020, and insufficient testing infrastructure, while proposing reforms such as permanent CDC field teams for outbreak detection and investments in rapid vaccine platforms. It draws on Gottlieb's experience as FDA commissioner from 2017 to 2019, critiquing institutional silos between agencies like the FDA, CDC, and NIH that hindered coordinated action. Gottlieb's second book, The Miracle Century: Making Sense of the Revolution, is scheduled for release by on April 14, 2026. It traces advancements in cell-based therapies, including CAR-T treatments for cancers like , highlighting scientific breakthroughs from the onward that enabled FDA approvals such as Kymriah in 2017 and Yescarta in the same year, and discusses regulatory challenges in scaling these personalized medicines. The work emphasizes the potential of cell therapies to transform and autoimmune diseases, informed by Gottlieb's post-FDA roles in advisory. Prior to his books, Gottlieb contributed to peer-reviewed literature on regulatory topics, including a 2017 New England Journal of Medicine perspective co-authored with Daniel Carpenter on restoring trust in U.S. therapeutics amid industry relationships, advocating for science-based transparency over restrictive conflicts policies. He also published analyses on FDA reorganization challenges in outlets like Health Affairs, warning of risks to drug review efficiency from structural changes proposed in the early 2010s. These works reflect his pre-commissioner focus at the American Enterprise Institute on balancing innovation with safety in pharmaceutical oversight.

Op-eds, interviews, and media appearances

Gottlieb has authored op-eds in prominent outlets, often critiquing regulatory hurdles to and addressing threats like shifts and . In the Wall Street Journal, he maintained a weekly column from 2020 to 2021, emphasizing practical responses to the , such as on March 29, 2020, co-authoring "The Road Back to Normal: More, Better Testing" to rapid diagnostics and enhancements, and on April 19, 2020, "How to Keep Workers Healthy on the Job," recommending staggered breaks, surface sanitization, and on-site testing for employers. He has also contributed to the Washington Post, including a September 22, 2025, piece asserting 's biotech advantages stem from policy speed rather than scientific superiority, urging U.S. reforms to retain . In STAT News, on May 6, 2025, he outlined policy measures to counter the of to , highlighting incentives like tax credits for domestic R&D. Gottlieb's New York Times contributions include a March 4, 2025, op-ed calling for intensified U.S. port and mail interdiction to curb fentanyl imports, arguing current efforts insufficiently target precursor chemicals from abroad. Earlier pieces, such as on AIDS treatments, warned against overhyping therapies without sustained evidence. He co-authored commentaries on FDA updates for diagnostics and cosmetics in outlets like Duke-Margolis policy forums, as on December 5, 2022. In media interviews, Gottlieb frequently appears as a CNBC contributor, discussing regulatory and market issues; on August 1, 2025, he praised initial efforts to lower drug prices under President as a viable starting point while cautioning on implementation. On February 21, 2025, he analyzed Department of Justice probes into billing at . He has featured on CBS's , including a June 29, 2025, interview on vaccine policy and board roles at , and an extended September 19, 2021, discussion of U.S. response shortcomings. C-SPAN archives document 41 appearances since a 2005 hearing, covering FDA oversight and health reforms. Gottlieb has engaged in Fox News segments on pandemic lessons, such as August 26, 2025, rundowns critiquing early COVID missteps and emphasizing preparedness. Other venues include a full April 2, 2025, Politico Health Care Summit interview on policy priorities, and Brookings events reflecting on his FDA tenure in 2019. His commentary often prioritizes evidence-based acceleration of approvals and over precautionary delays.

Recognition and affiliations

Awards and professional honors

In 2019, Gottlieb received the Dr. Nathan Davis for Outstanding Government Service from the , recognizing his as FDA Commissioner in advancing public health priorities such as drug approval efficiency and . That same year, he was honored with the by Friends of for contributions to policy, including accelerated approvals for cancer therapies during his FDA tenure. Also in 2019, Samford University's Healthcare Ethics and Law Institute awarded him the Edmund D. Pellegrino for exemplary achievement in healthcare ethics, citing his policy work balancing innovation with . Gottlieb was named twice to Fortune magazine's list of the World's 50 Greatest Leaders, reflecting recognition for his FDA reforms and subsequent public health advocacy. Time magazine similarly honored him as one of 50 people transforming healthcare, highlighting his influence on regulatory modernization and pandemic preparedness. In 2022, the American Society of Health-System Pharmacists (ASHP) presented Gottlieb with its Board of Directors Award of Honor, the organization's highest recognition for non-members, for advancing medication safety, supply chain resilience, and pharmacy policy. That year, he also received the Keystone Policy Center Leadership Award for bipartisan contributions to health policy dialogue.

Current board seats and fellowships

Gottlieb serves on the board of directors of Pfizer Inc., having joined in June 2019. He also holds board positions at Illumina Inc., where he was elected non-executive chair in 2025; Aetion Inc.; and Tempus AI Inc. As a senior fellow at the (AEI), Gottlieb focuses on studies, a role he resumed in 2019 following his tenure as FDA commissioner. He is additionally a partner on the healthcare investment team at (NEA), a firm, contributing to investments in and healthcare innovation.

Personal life

Family and personal background

Scott Gottlieb was born on June 11, 1972, in , where he grew up in a Jewish family. His father, Stanley Gottlieb, is a physician and veteran, while his mother worked as a Hebrew teacher. Gottlieb graduated from before earning a in economics from . He later obtained his medical degree from the Icahn School of Medicine at Mount Sinai and completed a residency in at . Gottlieb married Allyson Brooke Nemeroff on June 13, 2004; she is a graduate of the and the daughter of a Manhattan-based dentist. The couple has three daughters, including a set of twins who are the oldest. They reside in .

Interests and residence

Gottlieb resides in Westport, Connecticut, with his wife, Allyson Nemeroff Gottlieb, and their three daughters. He purchased the family's home on Red Coat Road for $1.8 million; town records assess its value at $1.75 million. During his tenure as FDA commissioner from 2017 to 2019, Gottlieb commuted weekly from Westport to Washington, D.C., a schedule he cited as a key factor in his resignation to prioritize family time. Public records indicate no additional properties directly tied to him in the area beyond this primary residence. Limited verifiable information exists on Gottlieb's personal hobbies or avocational pursuits outside his professional focus on healthcare policy and investing. He has occasionally engaged with local communities, such as addressing middle school students on topics in nearby in 2019.

References

  1. [1]
    Scott Gottlieb | FDA
    Feb 21, 2020 · Dr. Scott Gottlieb served as the 23rd Commissioner of Food and Drugs on May 11, 2017 to April 5, 2019. Dr. Gottlieb is a physician, medical policy expert, and ...
  2. [2]
    Scott Gottlieb | American Enterprise Institute - AEI
    Scott Gottlieb, MD, is a senior fellow at the American Enterprise Institute (AEI). He returned to AEI in 2019 after serving as the 23rd commissioner of the Food ...
  3. [3]
    [PDF] Scott Gottlieb, MD
    From 2005-2007, Dr. Gottlieb served as. FDA Deputy Commissioner for Medical and Scientific Affairs and before that, from 2003-2004, as a senior advisor to the ...
  4. [4]
    Cue the 'revolving door' criticism: Former FDA commissioner Gottlieb ...
    Jun 28, 2019 · When former FDA commissioner Scott Gottlieb, M.D., resigned back in March, he said he wanted to spend more time with his family.Missing: achievements | Show results with:achievements
  5. [5]
    Scott Gottlieb, MD, NEA Partner
    Scott is a Partner on NEA's Healthcare team. He was Venture Partner at NEA from 2007 to 2017, until being appointed the 23rd Commissioner of the U.S. Food and ...
  6. [6]
    Scott Gottlieb, M.D. - Pfizer
    Served as the 23rd Commissioner of the FDA from 2017 to 2019. Prior to serving as Commissioner of the FDA, Dr. Gottlieb held several roles in the public and ...
  7. [7]
    Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith ...
    Scott Gottlieb, MD, has been elected non-executive Chair of Illumina's Board. Dr. Gottlieb has served on the Board of Directors since 2020.Missing: positions | Show results with:positions
  8. [8]
    Scott Gottlieb - IMDb
    Scott Gottlieb was born on 11 June 1972 in East Brunswick, New Jersey, USA. ... - present (3 children). Other works. Release of his book, "Uncontrolled ...
  9. [9]
    WEDDINGS/CELEBRATIONS; Allyson Nemeroff, Scott Gottlieb
    Jun 13, 2004 · Scott Gottlieb, the son of Marsha Gottlieb and Dr. Stanley Gottlieb of East Brunswick, N.J. Rabbi Chaim Rogoff will officiate at the 3 West Club ...Missing: parents | Show results with:parents
  10. [10]
    Commissioner of the Food and Drug Administration: Who Is Scott ...
    Apr 24, 2017 · He grew up in East Brunswick, son of Stanley, a psychiatrist, and Marsha Gottlieb. Gottlieb attended Wesleyan University in Connecticut, where ...Missing: parents | Show results with:parents
  11. [11]
    [PDF] SCOTT GOTTLIEB - National Journal
    Family and Personal Background. Criticisms and Controversies. Close relationship with his family. • Mother worked as a Hebrew teacher and father is a physician ...Missing: early upbringing
  12. [12]
    FDA head Scott Gottlieb, a vaping opponent, stepping down after 2 ...
    Mar 7, 2019 · Gottlieb, who is Jewish, told his staff on Tuesday that he will leave his post next month, citing “the challenge of being apart from my family.Missing: influences upbringing
  13. [13]
    Dr. Scott Gottlieb, MD - Parker Institute for Cancer Immunotherapy
    Dr. Scott Gottlieb, MD, served as the 23rd Commissioner of the U.S. Food and Drug Administration and is currently a partner at the venture capital firm New ...
  14. [14]
    Scott Gottlieb, MD - NIHCM Foundation
    He completed a residency in internal medicine at the Mount Sinai Medical Center in New York and is a graduate of the Mount Sinai School of Medicine and Wesleyan ...Missing: training | Show results with:training
  15. [15]
    Dr. Scott Gottlieb, former US FDA Commissioner, joins ... - Illumina, Inc.
    Feb 6, 2020 · Dr. Gottlieb has a medical degree from Mount Sinai School of Medicine and completed his residency in internal medicine at the Mount Sinai ...Missing: education training
  16. [16]
    Scott Gottlieb | Milken Institute
    Scott Gottlieb served as the 23rd Commissioner of the Food and Drug Administration (FDA) from May 2017 to April 2019. A medical policy expert and public health ...Missing: first | Show results with:first
  17. [17]
    Trump Picks Dr. Scott Gottlieb For FDA Commissioner - NPR
    Mar 10, 2017 · An internist and hospitalist, Gottlieb has played leading roles in various government health agencies, including as deputy commissioner for ...Missing: background initial positions
  18. [18]
    Gottlieb, Scott - AllGov - Officials
    Gottlieb attended Mount Sinai School of Medicine at NYU, earning his M.D. in 1999 and finishing his residency in internal medicine there in 2002. Gottlieb ...Missing: professional background initial
  19. [19]
    Scott Gottlieb preps for FDA's top post with a resume that cuts two ...
    Apr 5, 2017 · In 2005, he returned to FDA as deputy commissioner for medical and scientific affairs. His signature accomplishment: helping to launch President ...
  20. [20]
    [PDF] Scott Gottlieb, MD
    From 2005-2007, Dr. Gottlieb served as. FDA Deputy Commissioner for Medical and Scientific Affairs and before that, from 2003-2004, as a senior advisor to the ...Missing: positions | Show results with:positions
  21. [21]
    Senate confirms new FDA commissioner | AuntMinnie
    The Senate voted 57 to 42 to confirm Gottlieb, a physician who had served at the FDA as deputy commissioner for medical and scientific affairs from 2005 to 2007 ...<|separator|>
  22. [22]
    Scott Gottlieb: Conflicts surround Trump's FDA pick - CNN
    Apr 4, 2017 · He was FDA deputy commissioner in the George W. Bush administration, did a yearlong stint as senior adviser to the administrator at the Centers ...
  23. [23]
    Four things Americans should know about Dr. Scott Gottlieb, the new ...
    May 10, 2017 · Gottlieb has been critical of President Trump 's key proposal to drive down the cost of prescription drugs: allowing their importation from ...Missing: achievements | Show results with:achievements
  24. [24]
    Scott Gottlieb | The Minor Consult - Stanford Medicine
    Prior to serving as FDA Commissioner, Dr. Gottlieb held several roles in the public and private sector including Managing Director of T.R. Winston & Company ...Missing: 1999 | Show results with:1999
  25. [25]
    F.D.A. Nominee, Paid Millions by Industry, Says He'll Recuse ...
    Mar 29, 2017 · Scott Gottlieb made millions of dollars doing work for more than 20 health care companies in the private sector.
  26. [26]
    Scott Gottlieb - Wikipedia
    Scott Gottlieb (born June 11, 1972) is an American physician and investor who previously served as the 23rd commissioner of the Food and Drug Administration ( ...
  27. [27]
    Scott Gottlieb wins confirmation as FDA commissioner - STAT News
    May 9, 2017 · By a vote of 57 to 42, the Senate on Tuesday confirmed Gottlieb, a former FDA deputy commissioner, as the agency's next chief.Missing: date | Show results with:date
  28. [28]
    Roll Call Vote 115 th Congress - 1 st Session - Senate.gov
    May 9, 2017 · Question: On the Nomination (Confirmation Scott Gottlieb, of Connecticut, to be Commissioner of Food and Drugs, Department of Health and Human ...Vote Summary · By Senator Name · By Vote Position
  29. [29]
    Scott Gottlieb: charting the achievements of outgoing FDA ...
    May 28, 2019 · On top of overseeing the approval of a record number of drug approvals in 2018 – 13 more than the 46 in 2017 – what were Gottlieb's main ...
  30. [30]
    Gottlieb leaves mixed legacy on drug prices, opioids, tobacco use
    Mar 6, 2019 · As a former adviser to several federal entities, FDA Commissioner Scott Gottlieb, MD was familiar with public service before he assumed his ...
  31. [31]
    FDA commissioner Scott Gottlieb to step down - C&EN
    Mar 8, 2019 · His brief stint as agency chief brought progress in approving generic drugs and advancing new technologies
  32. [32]
    FDA chief Scott Gottlieb, who raised alarms about teen vaping, to ...
    During his tenure, the FDA engineered the removal of the opioid medication Opana ER from the market, the first time the agency requested that action on public ...Missing: reforms | Show results with:reforms
  33. [33]
    FDA Commissioner Gottlieb, who raised alarms about teen vaping ...
    Mar 5, 2019 · In his resignation letter to Azar, Gottlieb ticked off a list of accomplishments, including accelerating the approval of generic drugs and ...Missing: achievements | Show results with:achievements
  34. [34]
    U.S. FDA chief tough on e-cigarettes steps down abruptly - Reuters
    Mar 5, 2019 · Under Gottlieb, the FDA proposed a ban on the sale of fruit- and candy-flavored electronic cigarettes in convenience stores and gas stations.Missing: vaping | Show results with:vaping
  35. [35]
    FDA moves on vaping, drugs and food at risk with chief's departure
    Mar 6, 2019 · Gottlieb's initiatives on nutrition and vaping, along with overhauling regulation of dietary supplements, often were at odds with Republican ...
  36. [36]
    FDA Commissioner Scott Gottlieb Announces He Will Resign - NPR
    Mar 5, 2019 · The commissioner of the Food and Drug Administration, Scott Gottlieb, announced Tuesday that he is resigning the position, effective in one month.Missing: key | Show results with:key
  37. [37]
    Scott Gottlieb - Ballotpedia
    Scott Gottlieb served as commissioner of the Food and Drug Administration from May 2017 to April 2019. Gottlieb announced on March 5, 2019, that he would ...
  38. [38]
    NEA Welcomes Scott Gottlieb, M.D., as Special Partner
    Gottlieb is an elected member of the National Academy of Medicine and currently a Resident Fellow at the American Enterprise Institute (AEI) in Washington, DC.
  39. [39]
    Scott Gottlieb Elected to Pfizer's Board of Directors
    Jun 27, 2019 · Dr. Gottlieb, a physician and medical policy expert, is currently a Special Partner of New Enterprise Associations, Inc.'s healthcare investment ...Missing: Associates | Show results with:Associates<|control11|><|separator|>
  40. [40]
    Former FDA Commissioner Gottlieb joins health startup Aetion's ...
    Sep 17, 2019 · Former Food and Drug Administration (FDA) Commissioner Scott Gottlieb, MD, has added another position to his roster of board and advisory roles.
  41. [41]
    Scott Gottlieb, M.D. | Board Director - Aetion
    Scott Gottlieb, M.D. serves as a Board Director at Aetion, a health care technology company that turns real-world data into regulatory grade evidence.Missing: positions | Show results with:positions<|control11|><|separator|>
  42. [42]
    Dr. Scott Gottlieb, former US FDA Commissioner, joins ... - Illumina
    Illumina, Inc. (NASDAQ: ILMN) announced today that Scott Gottlieb, MD has joined the company's Board of Directors, effective February 4, 2020.
  43. [43]
    Scott Gottlieb - Partner @ New Enterprise Associates - Crunchbase
    Scott Gottlieb holds 4 board and advisor roles including Board Member at Comanche Biopharma , Board Member at Resilience , and Member of the Board of Directors ...Missing: positions | Show results with:positions
  44. [44]
    Scott Gottlieb Bio | | Xaira Therapeutics
    Scott Gottlieb, MD, is a physician and served as the 23rd Commissioner of the US Food and Drug Administration. He is currently a senior fellow at the American ...
  45. [45]
    FDA Under the Trump Administration: Can Scott Gottlieb Improve the ...
    Dr Gottlieb will be tasked with implementing the 21st Century Cures Act, which was signed by President Obama to help speed the development and approval of drugs ...
  46. [46]
    Former FDA Commissioner: 'Cost-Cutting' May Undo One of Trump's ...
    May 28, 2025 · The FDA approved a record-breaking number of generic drugs in 2017 and 2018, yielding an estimated $26 billion in savings for American consumers.<|control11|><|separator|>
  47. [47]
    Trump's FDA Pick Is Speeding Up New Drug Approvals - Newsweek
    Feb 2, 2018 · The Gottlieb FDA has also signaled it will approve "broad labels" for drugs. That means drugs can be prescribed to a larger patient population.
  48. [48]
    What FDA Is Doing to Lower Rx Prices, Congress Can Help
    Apr 26, 2018 · FDA Commissioner Scott Gottlieb has proposed a meaningful agenda to lower prescription drug prices by encouraging competition and transparency in drug markets.
  49. [49]
    Gottlieb Defends Accelerated Approval, Scorns Access Limits By ...
    Oct 23, 2017 · US FDA's accelerated approval pathway is more reliable and has better validated biomarkers than a decade ago, commissioner says, ...Missing: views speeding
  50. [50]
    Antitrust Concerns and The FDA Approval Process
    Feb 20, 2018 · Statement of Scott Gottlieb, M.D. Commissioner of Food And Drugs, Food and Drug Administration, before the House Committee on the Judiciary, ...
  51. [51]
    China's edge over U.S. biotech was never scientific
    Sep 22, 2025 · Opinion | Scott Gottlieb: The FDA should match China in speeding drug discovery - The Washington Post.
  52. [52]
    Former FDA Leaders Say New Policies Needed to Boost Medical ...
    Sep 26, 2025 · Advances in rare disease treatments and clinical trial tools demand new regulatory frameworks, former commissioners say at Schaeffer Center ...
  53. [53]
    Gottlieb calls for FDA reform, investment to counter Chinese medical ...
    Sep 23, 2025 · Gottlieb calls for FDA reform, investment to counter Chinese medical innovation. Former US Food and Drug Administration (FDA) Commissioner ...Missing: processes | Show results with:processes
  54. [54]
    FDA Commissioner Releases a Statement on Opioids and How ...
    Feb 15, 2019 · In 2017, FDA took steps to expand the Risk Evaluation and Mitigation Strategy (REMS) program for opioids. The REMS program requires ...
  55. [55]
    FDA's Gottlieb calls for greater use of medication-assisted treatment ...
    Oct 25, 2017 · The greater use of such therapies, which combine medication and counseling, could help people reduce their illegal drug use, he testified.
  56. [56]
    The Federal Response to the Opioid Crisis - 10/04/2017 | FDA
    Oct 4, 2017 · Improve access to prevention, treatment, and recovery support services to prevent the health, social, and economic consequences associated with ...
  57. [57]
    [PDF] Statement by Scott Gottlieb, M.D. Commissioner of Food and Drugs ...
    Apr 2, 2019 · Supporting the treatment of those with opioid use disorder, • Fostering the development of novel pain treatment therapies, and • Increasing ...
  58. [58]
    FDA pushes for development of non-opioid pain medications - NCBI
    New advice to industry will aim to provide clarity on nonaddictive alternatives, FDA Commissioner Scott Gottlieb says.Missing: initiatives | Show results with:initiatives
  59. [59]
    [PDF] Federal Regulatory Responses to the Prescription Opioid Crisis
    83 See Scott Gottlieb & Janet Woodcock, Marshaling FDA Benefit-Risk Expertise to. Address the Current Opioid Abuse Epidemic, 318 JAMA 421, 421–22 (2017); Jeanne.<|separator|>
  60. [60]
    How FDA Failures Contributed to the Opioid Crisis | Journal of Ethics
    This article explores regulatory mistakes made by the US Food and Drug Administration (FDA) in approving and labeling new analgesics.
  61. [61]
    Statement from FDA Commissioner Scott Gottlieb, M.D., on the ...
    Nov 2, 2018 · Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency's continued efforts to address growing epidemic of youth e-cigarette use, ...
  62. [62]
    FDA tightens restrictions on flavored e-cigarettes to curb teen vaping
    Mar 13, 2019 · Outgoing FDA chief Scott Gottlieb releases a much-anticipated draft policy restricting e-cigarette sales to curb an "epidemic" of teen use.
  63. [63]
    FDA finalizes compliance policy for certain activities at vape shops
    Mar 22, 2019 · As part of continuing efforts to advance robust framework for oversight of e-cigarettes, FDA has finalized compliance policy for certain ...
  64. [64]
    FDA chief threatens to take e-cigarettes off the market - NBC News
    Jan 18, 2019 · Last November, Gottlieb said he was starting the process to limit sales of flavored e-cigarettes, as well as to ban menthol in combustible ...
  65. [65]
    Gottlieb announces FDA steps to address opioid epidemic, nicotine ...
    Gottlieb noted that earlier this year FDA requested Endo Pharmaceuticals to withdraw its reformulated Opana ER from the market, as a result of a risk analysis ...
  66. [66]
    FDA's Comprehensive Plan for Tobacco and Nicotine Regulation
    Jan 6, 2022 · This plan serves as a multi-year roadmap to better protect youth and help addicted adult smokers quit, significantly reducing tobacco-related disease and death ...
  67. [67]
    FDA Commissioner Advocates Against Smoking, New Vaping Devices
    Feb 20, 2019 · “I will not allow a generation of children to become addicted to nicotine through e-cigarettes.” Gottlieb said in November 2018. “We won't let ...
  68. [68]
    Former FDA chief Gottlieb: 'We struck the wrong balance' on e ...
    May 21, 2019 · While commissioner, Gottlieb championed e-cigarettes as a way to help adults stop smoking. The agency's delayed oversight has been blamed, in ...
  69. [69]
    Uncontrolled Spread: Why COVID-19 Crushed Us and How We Can ...
    In “Uncontrolled Spread,” physician and former Food and Drug Administration Commissioner Scott Gottlieb shows how COVID-19 was able to trounce America's ...
  70. [70]
    Why the U.S. pandemic playbook was no match for COVID - NPR
    Oct 6, 2021 · In his new book, former FDA Commissioner Scott Gottlieb lays out what it will take for the U.S. to be ready to face future health crises.
  71. [71]
    Uncontrolled Spread: A new book from Dr. Scott Gottlieb
    Dr. Scott Gottlieb identifies the reasons why the US was caught unprepared for the pandemic and how the country can prepare for future viral threats.
  72. [72]
    Lessons from the pandemic: the mistakes that led to uncontrolled ...
    May 4, 2022 · Scott Gottlieb, senior fellow at the American Enterprise Institute, former FDA chair, and author of Uncontrolled Spread. They discuss how ...<|separator|>
  73. [73]
    Scott Gottlieb has a plan to 'fix' CDC. Not everyone is on board.
    Jan 24, 2023 · Overall, Gottlieb said CDC should return to its roots and focus on "moving quickly to mitigate dangers from known pathogens and prevent future ...Missing: preparedness | Show results with:preparedness
  74. [74]
    Scott Gottlieb on Covid, a better CDC, and how he does it all | STAT
    Sep 24, 2021 · His book about the pandemic, “Uncontrolled Spread: Why COVID-19 Crushed Us and How We Can Defeat the Next Pandemic,” was released Tuesday.
  75. [75]
    Former FDA Head Scott Gottlieb: Why Pandemic Prep Failed, Who ...
    Sep 29, 2021 · An apolitical take, Gottlieb's assessment allows us to step away from the political narrative of the Covid-19 pandemic and to focus instead on ...Missing: views | Show results with:views
  76. [76]
    Gottlieb to FDA: Partner with Industry to Accelerate COVID-19 ...
    Apr 20, 2020 · Dr. Gottlieb is urging the FDA and industry to identify the one or two strongest vaccine contenders and focus all clinical trials on those. Be ...
  77. [77]
    Dr. Gottlieb: Getting Covid vaccine doesn't mean people can return ...
    Jan 6, 2021 · Scott Gottlieb: Getting Covid vaccine doesn't mean people can just return to pre-pandemic life. "It's not going to be like it was in 2017 and ...
  78. [78]
    Ex-FDA Commissioner Gottlieb Says Biden's Vaccine Mandate ...
    Sep 14, 2021 · NPR's A Martínez speaks to former FDA commissioner Dr. Scott Gottlieb about the potential backlash to the Biden administration's vaccine-or-testing plan.Missing: policy | Show results with:policy
  79. [79]
    Trump's former FDA commissioner: 'It will cost lives in this country' if ...
    Nov 30, 2024 · “You're going to see measles, mumps and rubella vaccination rates go down,” Gottlieb, who led the FDA under Trump's first administration, added.Missing: perspectives | Show results with:perspectives
  80. [80]
    Dr. Scott Gottlieb on CDC's new vaccine advisory board - CNBC
    Jun 26, 2025 · Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss new members of the CDC's new vaccine advisory board, what to expect in the new vaccine ...Missing: perspectives | Show results with:perspectives
  81. [81]
    Dr. Gottlieb: RFK Jr. is an avowed anti-vaxxer, 'sometimes you have ...
    Sep 8, 2025 · Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to ... vaccine safety, and more. For access to live and exclusive video ...Missing: policy | Show results with:policy
  82. [82]
    By The Numbers: Trump's Choice For FDA Chief Is Versatile ...
    Mar 15, 2017 · Gottlieb serves or served on eight boards of directors, according to his LinkedIn profile. The firms include pharmaceutical companies Gradalis ...Missing: seats | Show results with:seats
  83. [83]
    7 things to know about Dr. Scott Gottlieb's relationship with the drug ...
    or has served — on eight boards of directors for companies like Tolero Pharmaceuticals, which develops cancer ...Missing: connections seats
  84. [84]
    Gottlieb joins Pfizer's board | C&EN Global Enterprise
    Former US Food and Drug Administration commissioner Scott Gottlieb, who returned to the private sector in April, has joined the board of Pfizer.
  85. [85]
    Former FDA Commissioner Gottlieb defends decision to join Pfizer ...
    a job that paid a minimum of $335000 in stock and cash in 2018.
  86. [86]
    Outrage of the Month: Revolving Door to FDA Commissioner's Office ...
    Public Citizen strongly opposed Gottlieb's nomination to be FDA Commissioner because of his deeply rooted ties to Big Pharma that spanned more than a decade.
  87. [87]
    Senator Warren Calls on Former FDA Commissioner Scott Gottlieb ...
    Jul 2, 2019 · Senator Warren calls on former FDA Commissioner Scott Gottlieb to resign from pharmaceutical giant Pfizer's board of directors.
  88. [88]
    Scott Gottlieb defends his decision to join Pfizer's board - YouTube
    Jul 2, 2019 · Former FDA Commissioner Scott Gottlieb was recently elected to the board of Pfizer. He joins "Squawk Box" to discuss his decision.<|separator|>
  89. [89]
    Trump chooses Gottlieb to run FDA; Pharma breathes sigh of relief
    Mar 11, 2017 · U.S. President Donald Trump has chosen Dr. Scott Gottlieb, a conservative health policy expert with deep ties to the pharmaceutical industry ...
  90. [90]
    Venture Capitalist Gottlieb Has Too Many Conflicts to Run FDA
    Apr 4, 2017 · Aside from the tangle of industry ties, Dr. Gottlieb has advocated a dangerous deregulatory approach to the review process for new medications.
  91. [91]
    Why We Oppose Scott Gottlieb to Head the FDA
    Gottlieb's nomination given his criticism of government restrictions on how companies could market drugs for off-label uses. We need an FDA Commissioner who ...Missing: achievements controversies<|separator|>
  92. [92]
    Gottlieb as FDA commissioner would be music to pharma's ears
    Apr 4, 2017 · Gottlieb has criticized government efforts to shed light on conflicts of interest, such as the Physician Sunshine Act, as “federal tinkering” ...
  93. [93]
    What Does Scott Gottlieb's Leadership Mean for Scientific Integrity at ...
    May 9, 2017 · The revolving door at the FDA is dangerous: “By stopping the revolving door of industry people who are brought into high level positions ...Missing: allegations | Show results with:allegations
  94. [94]
    Elizabeth Warren Calls on Former F.D.A. Chief to Quit Pfizer Board
    Jul 2, 2019 · The Democratic presidential candidate rebuked Dr. Scott Gottlieb, saying his decision to align with a major drug company “smacks of ...Missing: allegations | Show results with:allegations<|separator|>
  95. [95]
    'Something very rare': FDA's Gottlieb aggressively tackled ... - Politico
    Mar 5, 2019 · Gottlieb pushed regulatory issues under a mandate from a president that pushed deregulation as one of his core goals. He was also outspoken on ...Missing: debates | Show results with:debates
  96. [96]
    Scott Gottlieb's fervor for deregulation could harm patients
    Mar 16, 2017 · A trial that began in a federal courtroom in Boston in January is a timely reminder of how the laissez-faire regulatory posture that Gottlieb is ...Missing: criticisms | Show results with:criticisms
  97. [97]
    Gottlieb could speed up FDA drug approvals - Axios
    The FDA's drug approval process is already faster than the European Union's agency. Researchers found that the FDA took an average of 306 days to approve 170 ...
  98. [98]
    Gottlieb: New drug approval criteria limited to opioids - Axios
    Nov 12, 2018 · Why it matters: There's long been a debate over whether new drugs should be approved or rejected in the context of what's already on the market.
  99. [99]
    Statement from FDA Commissioner Scott Gottlieb, M.D., on agency's ...
    We should consider whether we could do more in weighing approvals to ensure that new opioids are sufficiently better than existing drugs to justify their ...
  100. [100]
    Senator Markey Cites Concerns Over Opioid Crisis, Need to Reform ...
    Mar 15, 2017 · Gottlieb has expressed opposition towards FDA process for ensuring safe use of opioids and other prescription drugs.Missing: vaping | Show results with:vaping<|control11|><|separator|>
  101. [101]
    - NOMINATION OF SCOTT GOTTLIEB, M.D., TO SERVE AS ...
    - NOMINATION OF SCOTT GOTTLIEB, M.D., TO SERVE AS COMMISSIONER OF FOOD AND DRUGS.
  102. [102]
    Scott Gottlieb was the most aggressive anti-tobacco FDA leader in ...
    Mar 6, 2019 · For these reasons, health groups sued the FDA over the delay and sent a letter to Gottlieb asking the FDA to begin to regulate e-cigarette ...Missing: controversy | Show results with:controversy
  103. [103]
    Uncontrolled Spread: Why COVID-19 Crushed Us and How We Can ...
    In Uncontrolled Spread, he shows how the coronavirus and its variants were able to trounce America's pandemic preparations, and he outlines the steps that must ...Missing: arguments | Show results with:arguments
  104. [104]
    Uncontrolled Spread by Scott Gottlieb - Porchlight Book
    Uncontrolled Spread is everything you'd hope: a smart and insightful account of what happened and, currently, the best guide to what needs to be done to avoid ...
  105. [105]
    The Miracle Century - HarperCollins Publishers
    In stock Free delivery over $35The Miracle Century. Making Sense of the Cell Therapy Revolution. By Scott Gottlieb,. On Sale: April 14, 2026. $30.00.<|separator|>
  106. [106]
    Scott Gottlieb and the Credibility of U.S. Therapeutics
    Publication information: D C. Scott Gottlieb and the Credibility of U.S. Therapeutics. The New England Journal of Medicine. 2017;376(15) ...Missing: major | Show results with:major
  107. [107]
    Scott Gottlieb's research works | American Enterprise Institute and ...
    Scott Gottlieb's 15 research works with 86 citations, including: Why a Planned Reorganization of the FDA Creates Major Challenges.
  108. [108]
    https://www.wsj.com/articles/the-road-back-to-normal-more-better-testing-11585503340
  109. [109]
    https://www.wsj.com/articles/how-to-keep-workers-healthy-on-the-job-11587311057
  110. [110]
    How to stop the shift of drug discovery from the U.S. to China
    Scott Gottlieb, M.D., is a senior fellow at the American Enterprise Institute and served as commissioner of the Food and Drug Administration ...
  111. [111]
    Scott Gottlieb, MD - X
    Mar 4, 2025 · My Op Ed from the @nytimes: To stop the fentanyl trade in U.S. we need to step up interdiction work at U.S. ports and mail facilities. Why?
  112. [112]
    Scott Gottlieb - The New York Times
    The Limits of the AIDS Miracle. Dr Scott Gottlieb Op-Ed article warns that glowing reports about new drug therapies to treat AIDS are unjustified and ...
  113. [113]
    Op-Eds/Commentaries - Duke-Margolis Institute for Health Policy
    Op-Ed - 12/5/2022 Congress needs to update FDA regulations on diagnostic tests and cosmetics By Scott Gottlieb, MD and Mark B. McClellan, MD
  114. [114]
    Pres. Trump's push to lower drug prices 'is a good starting ... - CNBC
    Aug 1, 2025 · Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. ...Missing: appearances | Show results with:appearances
  115. [115]
    DOJ investigating Medicare billing practices at UnitedHealth Group
    Feb 21, 2025 · DOJ investigating Medicare billing practices at UnitedHealth Group: WSJ. Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to ...
  116. [116]
    Transcript: Scott Gottlieb on "Face the Nation with Margaret Brennan ...
    Jun 29, 2025 · That he's taking on issues that he's championed for the last 20 years to restrict access to certain vaccines. That's going to grow. The list is ...
  117. [117]
    Dr. Scott Gottlieb on "Face the Nation" with Margaret Brennan, Part 1.
    Sep 20, 2021 · In this extended version of an interview that aired on Sunday, September 19, 2021, Dr. Scott Gottlieb discusses the missteps of the U.S. ...Missing: appearances | Show results with:appearances
  118. [118]
    Scott Gottlieb | C-SPAN.org
    Scott Gottlieb was a Commissioner for the U.S. Food and Drug Administration with 41 videos in the C-SPAN Video Library; the first appearance was a 2005 Senate ...
  119. [119]
    Dr. Scott Gottlieb On The Mistakes Made During ... - FOX One
    Aug 26, 2025 · Watch "Fox News Rundown Extra: Dr. Scott Gottlieb On The Mistakes Made During Coronavirus Pandemic" from FOX News Rundown on FOX One.Missing: CNN | Show results with:CNN
  120. [120]
    Full interview with former FDA head Scott Gottlieb - Politico
    Apr 2, 2025 · Full interview with former FDA head Scott Gottlieb | POLITICO Health Care Summit 2025. 04/02/2025 02:31 PM EDT. Browse Videos. Most Recent.Missing: media | Show results with:media
  121. [121]
    A conversation with departing FDA Commissioner Scott Gottlieb on ...
    Outgoing FDA Commissioner Scott Gottlieb to reflect on his tenure and policy reforms. Following his speech, Bloomberg reporter Anna Edney interviewed him.Missing: appearances | Show results with:appearances<|separator|>
  122. [122]
    AMA presents government service award to FDA commissioner
    Feb 13, 2019 · Dr. Gottlieb is one of eight honorees chosen this year to receive the Dr. Nathan Davis Award for Outstanding Government Service.
  123. [123]
    Dr. Scott Gottlieb Honored at 23rd Annual Cancer Leadership ...
    Sep 25, 2019 · Friends of Cancer Research honored Dr. Scott Gottlieb, Former ... Scott Gottlieb Honored at 23rd Annual Cancer Leadership Awards Reception.
  124. [124]
    Samford Names Scott Gottlieb and Farr Curlin its 2019 Pellegrino ...
    Sep 3, 2019 · Samford University's Healthcare Ethics and Law Institute is proud to announce the 2019 recipients of its Edmund Pellegrino Award for Healthcare Ethics.
  125. [125]
    Scott Gottlieb, MD, is the 2022 recipient | ASHP Award of Honor
    Jan 1, 2023 · He has been named twice to Fortune's 50 Greatest World. Leaders list and honored by Time as one of the top 50 people transforming healthcare. He ...
  126. [126]
    ASHP Board of Directors Awards
    Nov 14, 2022 · The 2022 Award of Honor recipient is Scott Gottlieb, MD, 23rd commissioner of the Food and Drug Administration (FDA) and senior fellow at the ...
  127. [127]
    Scott Gottlieb's Post - LinkedIn
    Jun 9, 2022 · I was honored to receive the Keystone Policy Center Leadership Award last night, where I was interviewed by bioethicist Dr. Arthur Caplan ...Missing: professional | Show results with:professional
  128. [128]
    Illumina Board of Directors
    Scott Gottlieb, MD. Chair of the Board. Scott Gottlieb, MD. Chair of the Board. Scott Gottlieb. Dr. Gottlieb has been a director since February 2020.
  129. [129]
    AARP's Interview With FDA Commissioner Scott Gottlieb
    Apr 6, 2019 · Fast facts · Born in New Jersey · Bachelor's degree from Wesleyan University · Medical degree from the Icahn School of Medicine at Mount Sinai ...
  130. [130]
    5 takeaways from Scott Gottlieb's surprising FDA departure
    Mar 6, 2019 · Gottlieb, 46, is husband to Allyson Nemeroff and father to three daughters. Their home is in Connecticut. Gottlieb noted to The Washington Post ...
  131. [131]
    Outgoing FDA chief Gottlieb gets personal about leaving 'the best job'
    back-to-school nights, school plays and parent- ...
  132. [132]
    Former FDA chief grabs spotlight with coronavirus plans to 'turn the ...
    Apr 13, 2020 · Gottlieb shot up warning flares in early January about the mysterious respiratory illness. Having worked in a hospital during the 2009 swine flu ...<|separator|>
  133. [133]
    Ex-FDA chief, CT adviser Gottlieb paid property taxes minutes after ...
    Apr 30, 2020 · His Westport home is assessed based on a total value of $1.75 million, according to town records. He bought the house on Red Coat Road for $1.8 ...
  134. [134]
    Outgoing FDA chief warns Weston students about vaping - CT Insider
    Mar 8, 2019 · ... Scott Gottlieb is trying to discourage children from involved with nicotine. Gottlieb, a Westport resident, spoke to Weston Middle School ...